{'fraction_non_alphanumeric': 0.020214030915576695, 'fraction_numerical': 0.007134363852556481, 'mean_word_length': 4.767123287671233, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Treatment of colon pseudo-obstruction in Guillain-Barré syndrome

PPI therapy and not changing to H2 receptor antagonists, especially as 60% of patients could be maintained on alternate-day or spaced therapy. Thus, our contention is that what one really needs to find is the optimally effective dose per patient, which is probably the best approach for the treatment of GERD or heartburn even if endoscopy is not used. One of the factors the authors have taken into consideration is the cost factor for advocating a step-down approach. However, it should be stressed that alternate-day or spaced therapy or finding the optimum effective dose for those 60% of patients who can manage with the step-down approach with the PPI might be even more cost effective than changing to a step-down H2 receptor antagonist with an unpredictable response.